Healthcare
Biotechnology
Technology

Acorda Therapeutics

$13.29
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.16 (1.22%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ACOR and other stocks, options, ETFs, and crypto commission-free!

About

Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its two main products are Ampyra and Zanaflex Capsules. Read More The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short acting drug for the management of spasticity, a symptom of many central nervous system disorders, including multiple sclerosis and spinal cord injury. The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.

Employees
474
Headquarters
Ardsley, New York
Founded
1995
Market Cap
622.63M
Price-Earnings Ratio
18.81
Dividend Yield
0.00
Average Volume
726.62K
High Today
$13.43
Low Today
$13.10
Open Price
$13.23
Volume
217.14K
52 Week High
$36.35
52 Week Low
$12.55

Collections

Healthcare
Biotechnology
Technology
Health
Therapy
US
North America

News

Yahoo Finance13h

See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.

Acorda Therapeutics Inc NASDAQ/NGS:ACOR View full report here! Summary Bearish sentiment is moderate Bearish sentiment Short interest | Negative Short interest is moderately high for ACOR with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flow ETF/Index ownership | Neutral ETF activit...

5
MarketWatchMar 25

Acorda Therapeutics Inc.

Acorda (ACOR) delivered earnings and revenue surprises of 175.00% and 70.38%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

22
TradingNewsNowMar 21

Recent Fundamentals: Acorda Therapeutics (NASDAQ: ACOR)

Acorda Therapeutics trades as part of the biotechnology industry and healthcare sector. The company CEO is Ron Cohen. Acorda Therapeutics Inc is a biopharmaceutical company. It is engaged in the identification, development and commercialization of novel therapies for the treatment of neurological disorders. Previous Intraday Trading Performance: The ACOR stock showed a previous change of -4.60% with an open at 14.36 and a close of 13.69. It reached an intraday high of 14.41 and a low of 13.51. Business W...

27

Earnings

-$0.63
$0.05
$0.72
$1.40
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 1
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.